Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00053625 · ClinicalTrials.gov registry record · Phase 3
Deep Brain Stimulation for Parkinson's Disease Trial
A Phase 3 study of Parkinson's Disease, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 3
- Development phase
- 123
- Enrollment target
- 2
- Study locations
NCT00053625: Completed Phase 3 study of Parkinson's Disease, sponsored by University of Minnesota.
NCT00053625 is a Phase 3 study of Parkinson's Disease that has completed, run by University of Minnesota. The registered enrollment target is 123 participants, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (81% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00053625, a Phase 3 study of Parkinson's Disease, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 123 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this trial is to evaluate the effect of deep brain stimulation in the the globus pallidus (Gpi) and the subthalamic nucleus (STN) on motor, neuropsychological and psychiatric function, and quality of life in patients with Parkinson's disease.
Primary Outcome
The Unified Parkinson's Disease Rating Scale (UPDRS) is a commonly used survey tool used to assess symptom severity of patients with Parkinson's disease (PD). It covers several different domains including 1) thought, behavior and mood 2) activities of daily living 3) motor activity 4) complications of therapy and others. The mean change from baseline to six months after DBS surgery for patients with DBS in the GPi vs the STN will be compared after being adjusted for differences in age and time s
Conditions Studied
Interventions
- PROCEDURE deep brain stimulation
Study Locations (2)
Georgia
- Emory University School of Medicine, Neurology Department - Atlanta
Ohio
- Cleveland Clinic Foundation - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 1999-06 |
| Est. Completion | 2009-06 |
| Phase | Phase 3 |
What the finished NCT00053625 record still lists
NCT00053625 is an interventional study that assigns participants to a tested intervention. The registered 123 participants enrollment target is mid-sized for trials with a published cap, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 1 intervention - of which deep brain stimulation is the first listed.
NCT00053625 reports a single indexed study location in Georgia, Ohio.
Frequently Asked Questions
What is clinical trial NCT00053625 about?
NCT00053625 is a clinical study titled "Deep Brain Stimulation for Parkinson's Disease Trial". The purpose of this trial is to evaluate the effect of deep brain stimulation in the the globus pallidus (Gpi) and the subthalamic nucleus (STN) on motor, neuropsychological and psychiatric function, and quality of life in patients with Parkinson's disease.
What is the current status of trial NCT00053625?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 123 participants. The study started on 1999-06. Estimated completion is 2009-06.
What conditions does trial NCT00053625 study?
This clinical trial studies the following conditions: Parkinson's Disease.
What interventions are being tested in trial NCT00053625?
The interventions under investigation include: deep brain stimulation (PROCEDURE).
Who is sponsoring clinical trial NCT00053625?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00053625 being conducted?
This trial has 2 study locations across Georgia, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00053625's enrollment target sits among peer trials
123 46th of 158 higher than 112 of 158 other Parkinson's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
RECRUITING · Phase 3
-
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
ACTIVE NOT RECRUITING · Phase 3
-
An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease
COMPLETED · Phase 3
-
Study of KW-6002 (Istradefylline) in Parkinson's Disease in Patients With Motor Response Complications on Levodopa
COMPLETED · Phase 3
-
An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease
COMPLETED · Phase 3
-
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05285891 · 123 participants · Phase 4
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
- NCT05334368 · 123 participants · Phase 3
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
- NCT06088355 · 123 participants · NA
Moderate Versus High Volume Light-Moderate Intensity Exercise for People With Moderate Parkinson's Disease
- NCT06111131 · 123 participants · NA
Ancora-SB Overtube Complete Positioning and Optical Visualization During Endoscopic Procedures
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia